Praxis Precision Medicines, Inc. (PRAX) stock
PRAXNasdaqPharmaceutical PreparationsFiscal year ends December 31
$310.27−17.86 (-5.44%)
Close on Nov 16, 2026Market cap $8.66BP/E –Yield –
Praxis Precision Medicines total assets
Total assets on the balance sheet at the end of each period.
Praxis Precision Medicines's total assets was $1.39B at Jun 30, 2026. For fiscal 2025 it was $937.91M, up 94.1% from the year before. The highest annual figure on record is $937.91M in fiscal 2025.
Annual total assets
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $937.91M | +94.1% |
| FY2024 | Dec 31, 2024 | $483.11M | +449.3% |
| FY2023 | Dec 31, 2023 | $87.95M | -23.6% |
| FY2022 | Dec 31, 2022 | $115.13M | -60.7% |
| FY2021 | Dec 31, 2021 | $292.75M | -3.4% |
| FY2020 | Dec 31, 2020 | $303.18M | +535.7% |
| FY2019 | Dec 31, 2019 | $47.69M | – |
Quarterly total assets
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | $1.39B | +207.0% |
| Q1 FY2026 | Mar 31, 2026 | $1.46B | +205.0% |
| Q4 FY2025 | Dec 31, 2025 | $937.91M | +94.1% |
| Q3 FY2025 | Sep 30, 2025 | $396.39M | -4.8% |
| Q2 FY2025 | Jun 30, 2025 | $452.83M | +2.7% |
| Q1 FY2025 | Mar 31, 2025 | $478.74M | +91.2% |
| Q4 FY2024 | Dec 31, 2024 | $483.11M | +449.3% |
| Q3 FY2024 | Sep 30, 2024 | $416.26M | +290.0% |
| Q2 FY2024 | Jun 30, 2024 | $441.06M | +230.4% |
| Q1 FY2024 | Mar 31, 2024 | $250.41M | +154.5% |
| Q4 FY2023 | Dec 31, 2023 | $87.95M | -23.6% |
| Q3 FY2023 | Sep 30, 2023 | $106.73M | -22.0% |
| Q2 FY2023 | Jun 30, 2023 | $133.50M | -26.0% |
| Q1 FY2023 | Mar 31, 2023 | $98.38M | -58.9% |
| Q4 FY2022 | Dec 31, 2022 | $115.13M | -60.7% |
| Q3 FY2022 | Sep 30, 2022 | $136.90M | -57.8% |
| Q2 FY2022 | Jun 30, 2022 | $180.42M | -49.0% |
| Q1 FY2022 | Mar 31, 2022 | $239.50M | -14.2% |
| Q4 FY2021 | Dec 31, 2021 | $292.75M | -3.4% |
| Q3 FY2021 | Sep 30, 2021 | $324.41M | +171.4% |
| Q2 FY2021 | Jun 30, 2021 | $353.51M | +641.2% |
| Q1 FY2021 | Mar 31, 2021 | $279.25M | – |
| Q4 FY2020 | Dec 31, 2020 | $303.18M | – |
| Q3 FY2020 | Sep 30, 2020 | $119.55M | – |
| Q4 FY2019 | Dec 31, 2019 | $47.69M | – |
See a number that looks wrong?